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The effect of sevoflurane postconditioning (sevo-postC) cardioprotection is compromised in diabetes which is associated with
increased oxidative stress.We hypothesized that antioxidant N-Acetylcysteine may enhance or restore sevo-postC cardioprotection
in diabetes. Control or streptozotocin-induced Type 1 diabetic rats were either untreated or treated with N-Acetylcysteine for four
weeks starting at five weeks after streptozotocin injection and were subjected to myocardial ischemia-reperfusion injury (IRI), in
the absence or presence of sevo-postC. Diabetes showed reduction of cardiac STAT3 activation (p-STAT3) and adiponectin with
concomitantly increase of FoxO1 and CD36, which associated with reduced sevo-postC cardioprotection. N-Acetylcysteine and
sevo-postC synergistically reduced the infarct size in diabetic groups. N-Acetylcysteine remarkably increased cardiac p-STAT3
which was further enhanced by sevo-postC. N-Acetylcysteine but not sevo-postC decreased myocardial FoxO1 while sevo-postC
but not N-Acetylcysteine significantly increased myocardiac adiponectin in diabetic rats. It is concluded that late stage diabetic
rats displayed reduction of cardiac p-STAT3, adiponectin deficiency, and increase of FoxO1 and CD36 expression, which may
be responsible for the loss of myocardial responsiveness to sevo-postC cardioprotection. N-Acetylcysteine restored Sevo-postC
cardioprotection in diabetes possibly through enhancing cardiac p-STAT3 and adiponectin and reducing Fox1 and CD36.
1. Introduction
Ischemic heart disease (IHD) is the main cause of morbidity
and mortality in diabetes. Patients with diabetes are particu-
larly at risk of perioperative myocardial infarction with con-
sequent ischemia and reperfusion injury (IRI). Sevoflurane
postconditioning (sevo-postC) has been shown to attenuate
myocardial IRI by restraining the adhesion of inflammatory
cells, blocking up free oxygen radicals, and preventing cal-
cium overload [1]. However, the beneficial effect of sevo-
PostC is markedly attenuated by diabetes and the underlying
mechanism is unclear. Diabetes can cause impairments to
both phosphatidylinositol 3-kinase- (PI3K-) Akt and Janus
kinase (Jak-) STAT3, which are the two classic signaling
pathways of myocardial protection mechanisms and thus
obstruct the postconditioning of myocardium [2, 3]. Recent
studies indicated that the inability of insulin to restore sevo-
postC cardioprotection in diabetes might be attributed to
diabetes-induced STAT3 mediated inhibition of PI3K signal-
ing [4]. Interestingly, our previous study has demonstrated
that antioxidantN-Acetylcysteine (NAC) can partially restore
the activation of Akt and STAT3 and subsequently attenuated
myocardial IRI in the early stage of diabetic rats [5, 6].
However, whether NAC can restore the cardioprotection
of sevo-IPostC through the restoration of STAT3 mediated
signaling remains unknown.
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FoxO transcription factors are important targets of
insulin in the myocardium [7, 8]. Three subfamily members
(FoxO1, O3, and O4) are critical for cardiac function [8]
and regulation of metabolism [9]. FoxO1 is dominant in the
adult heart. Cardiac specific activation of FoxO1 adversely
alters cardiac metabolism [10]. Studies have shown that
cardiac FoxO1 is increased in diabetes [11]. Deletion of
FoxO1 in cardiomyocytes shifts their metabolic substrate
usage from fatty acid (FA) to glucose and improves cardiac
function in subjects with insulin resistance [10]. In addition,
Akt phosphorylates/inactivates FoxO and confers cellular
protection [12]. Inactivation of FoxO1 also needs STAT3 [13].
These investigations suggest that FoxO1 is the downstream
target of both Akt and STAT3 and may play a critical
role in determining the progressive increase in myocardial
susceptibility to IRI in diabetic hearts.
Oxidative stress level is related to the expression of
adiponectin (APN), one of adipocytokines which protect
myocardium from IR [14]. Abundant evidence shows that
decreased APN is closely correlated with insulin resistance,
diabetes, and heart diseases. Our studies have shown that
NAC partially attenuated diabetic myocardial IRI through
restoration of APN mediated Akt and STAT3 activation
[6]. CD36 is known as one of scavenger receptors B and
serves as a critical factor in APN metabolism. It is mainly
expressed in macrophagocytes and plays an important role
in lipid metabolism [15–17]. Studies showed that CD36
could promote FA transfer under pathologic status [18, 19].
Hyperglycemia leads to a dose-dependent upregulation of
CD36 [20, 21], which was associated with the uptake of
FA in myocardium and contributed to cardiac contractile
dysfunction [22]. In addition, studies have shown that APN
negatively regulated FoxO1 [23]. FoxO increases mitochon-
drial CD36 [24, 25]. However, the roles of APN, FoxO1, and
CD36 in sevo-postC with or without NAC pretreatment in
diabetes have not been studied.
Therefore, we implement NAC treatment to 8-week
diabetic rats during feeding period and sevo-postC before
reperfusion to test the hypothesis that NAC and sevo-postC
can synergistically reduce myocardial IRI in diabetes and
explore the roles of p-STAT3, FoxO1, APN, and CD36 in this
procedure.
2. Methods
The experiment was permitted by the Moral and Ethical
Committee of Jinan University. Laboratory animals were
raised and used observing the Regulations for the Admin-
istration of Affairs concerning Experimental Animals of
Guangdong Province.
2.1. Establishment of T1DM Model. Male Sprague-Dawley
rats (300–350 g) were obtained from the Medical Laboratory
Animal Center of Guangdong and fed adaptively for 1 week.
T1DM was induced by a single intraperitoneal injection of
streptozotocin (Sigma, USA) at the dose of 65mg/kg. Blood
glucose was tested by a One Touch Ultra Vue glucometer
(Johnson,USA) 72 hours after the injection. Rats with a blood
glucose level higher than 16.7mmol/L were deemed T1DM.
2.2. Experimental Protocols. All rats were randomly divided
into 7 groups as follows:
Sham: non-diabetic control rats implemented thora-
cotomy without IR.
I (control): non-diabetic control rats implemented IR.
I + S: non-diabetic control rats subjected to IR and
sevo-postC.
T + I: T1DM rats implemented IR.
T + I + S: T1DM rats subjected to IR and sevo-postC.
T + I + N: T1DM rats treated with NAC and subjected
to IR.
T + I + S + N: T1DM rats treated with NAC and
subjected to IR and sevo-postC.
NAC (1.5 g/kg/day)was dissolved in drinkingwater [5] from5
to 8weeks after T1DMestablishment. Sevo-postCwas carried
out by persistently inhalation of 2% sevoflurane for 15min
before reperfusion. Food and water intake were record daily.
Weight and blood glucose were measured weekly. Ischemia
and reperfusion duration were, respectively, set as 30min
and 90min. Blood samples were collected from the inferior
vena cava at the end of reperfusion and plasma was extracted
and stored at −80∘C before detection. The ventricular tissue
was immediately frozen in liquid nitrogen and conserved at
−80∘C until assayed.
2.3. Myocardial Ischemia-Reperfusion In Vivo and Sevoflu-
rane Postconditioning. Rats were anaesthetized by intraperi-
toneal injection of pentobarbital (50mg/kg) and imple-
mented tracheal intubation.Mechanical ventilationwas given
using a ALC-V9B animal ventilator (Alcott Biotech, China).
Ischemia was achieved by ligation of the exposed left ante-
rior descending coronary artery (LAD) for 30min after
thoracotomy. Sevo-postC was accomplished by persistent
inhalation of 2% sevoflurane (Abbott, USA) through the
tracheal cannula for 15min in the latter half of ischemia,
followed by 90min of reperfusion.
2.4. Determination of Infarct Size. Rats’ hearts were dyed
by jugular vein injection of Evans Blue (Amresco, USA)
at the end of reperfusion and then cut off and stored at
−80∘C. The hearts were sliced and immersed in 1% 2,3,5-
triphenyltetrazolium chloride (TTC, Sigma, USA) solution
for 30min, making the area at risk (AAR) stained brick-
red and the normal area stained blue. Infarcted myocardium
which located in the AAR remained unstained. Infarct size
(IS) was signified as a percentage of AAR [26].
2.5. Detection of Plasma Troponin I (TnI) and Creatine Kinase-
MB (CK-MB). Plasma TnI value was estimated by an Ultra
Troponin I determination kit (Siemens, USA). Plasma CK-
MB levels were detected by a rat CK-MB elisa kit (Roche,
Swedish).
2.6. Western Blotting. Rat hearts were assembled from all
groups followed by the separation of heart tissues of the
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Table 1: General parameters during feeding period.
Groups Food intake (g/kg/day) Water intake (mL/kg/day) Weight (g) Blood glucose (mmol/L)
1–4 weeks 5–8 weeks 1–4 weeks 5–8 weeks 1–4 weeks 5–8 weeks 1–4 weeks 5–8 weeks
Sham 73 ± 4.9 69.1 ± 3.5 149.6 ± 5.4 165.6 ± 9.7 361.3 ± 13.0 433.0 ± 18.0 5.5 ± 0.3 5.3 ± 0.4
Control 76.5 ± 3.5 70.1 ± 1.5 154.5 ± 2.1 156.3 ± 0.6 360.5 ± 11.6 432.0 ± 11.2 5.4 ± 0.4 5.9 ± 0.3
I + S 67.2 ± 4.6 66.6 ± 2.2 155.2 ± 3.2 150.3 ± 3.0 370.0 ± 13.7 274.3 ± 9.2∗∗ 5.5 ± 0.3 5.7 ± 0.2
T + I 177.9 ± 24.1∗∗ 187.3 ± 2.9∗∗ 887.9 ± 158.3∗∗ 1118.8 ± 12.2∗∗ 271.3 ± 10.4∗∗ 238.8 ± 0.9∗∗ 28.0 ± 2.0∗∗ 29.5 ± 1.1∗∗
T + I + S 180.8 ± 19.4∗∗ 206.3 ± 1.6∗∗ 927.8 ± 170.5∗∗ 1224.0 ± 10.5∗∗ 274.3 ± 9.2∗∗ 271.3 ± 10.4∗∗ 26.9 ± 2.1∗∗ 26.1 ± 1.5∗∗
T + I + N 188.8 ± 24.2∗∗ 170.6 ± 6.5∗∗ 1072.5 ± 78.2∗∗ 614.1 ± 130.8∗∗&& 254.8 ± 15.7∗∗ 253.5 ± 4.6∗∗ 29.1 ± 1.2∗∗ 27.4 ± 2.5∗∗
T + I + N + S 192.5 ± 8.0∗∗ 154.5 ± 16.5∗∗& 1110.9 ± 52.5∗∗ 677.0 ± 105.2∗∗&& 253.3 ± 10.3∗∗ 269.5 ± 13.8∗∗ 26.3 ± 2.0∗∗ 27.5 ± 1.7∗∗
Data was expressed as mean ± SEM (𝑛 = 12); I, T, S, and N, respectively, stand for ischemia-reperfusion (I), Type 1 diabetes (T), sevoflurane (S), and N-
Acetylcysteine (N); control: ischemia-reperfusion untreated group.
∗∗
𝑃 < 0.01 compared with control group; &𝑃 < 0.05 and &&𝑃 < 0.01 compared with T + I group.
AAR. Heart tissues were homogenized using lysis buffer,
sonicated, and centrifuged at 12 000 g for 20min at 4∘C.
Protein concentrations were determined using the Bradford
assay (Bio-Rad, USA) and processed for western blotting
analysis as described [27, 28].The primary antibodies against
STAT3, p-STAT3 (Y705), FoxO1, CD36 (Abcam, England),
APN (CST, American), and GAPDH (Beyotime, China)
were used to detect corresponding protein expression of the
myocardium. Protein bands were observed by an Immobilon
Western Chemiluminescent HRP Substrate (Millipore, USA)
and then processed by gray scanning using Image J (National
Institutes of Health, USA).
2.7. Statistical Analysis. Experimental data was conveyed in
the shape of mean ± SEM. Differences between groups
and within group were analyzed with one-way ANOVA test
followed by LSD test for pairwise comparisons ofmeans using
SPSS 13.0 (SPSS, USA). 𝑃 < 0.05 was considered significant.
3. Results
3.1. General Parameters. As shown in Table 1, diabetic rats
displayed increased food intake, water intake, and blood
glucose and decreased body weight, compared with control
group (all 𝑃 < 0.01). NAC treatmentmarkedly reduced water
intake in diabetic rats (𝑃 < 0.01, T + I + N or T + I + S
+ N versus T + I). Compared with T + I group, T + I + S
+ N group showed decreased food intake and water intake
without significant impact on body weight during 5∼8 weeks
of diabetes. NAC had no effect on blood glucose levels in
diabetic rats when compared with T + I group.
3.2. Infarct Size. Measurements of infarct size after myocar-
dial IRIwere displayed in Figure 1. Compared to control, both
I + S and T + I + S + N groups showed decreased infarct
size compared with control group (𝑃 < 0.05). NAC treatment
together with sevo-postC dramatically decreased the infarct
size of diabetic rats, as compared with the T + I group (𝑃 <
0.01). NAC or sevo-postC alone did not have the noticeable
influence on the IS/AAR of diabetic hearts when compared
with T + I group.
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Figure 1: Comparison of IS/AAR% of rat hearts after 30min
ischemia followed by 90min reperfusion. Data was expressed as
mean ± SEM (𝑛 = 6 per group). I, T, S, and N, respectively, stand
for ischemia-reperfusion (I), Type 1 diabetes (T), sevoflurane (S),
and N-Acetylcysteine (N); control: ischemia-reperfusion untreated
group. ∗
𝑃
< 0.05 compared with control group; ∧∧
𝑃
< 0.01
compared with T + I group.
3.3. Plasma CK-MB and cTnI Levels. As indicated in
Figure 2(a), ischemia followed by reperfusion significantly
increased plasma CK-MB level and cTnI level in control
group (𝑃 < 0.05, control versus Sham). Sevo-postC exerted
no effect on CK-MB levels, while NAC largely reduced CK-
MB release in diabetic rats with or without sevo-postC (𝑃 <
0.05, T + I + N or T + I + S + N versus T + I). As shown in
Figure 2(b), sevo-postC significantly decreased cTnI levels in
control group (𝑃 < 0.01, I + S versus control). Sevo-postC
or NAC alone moderately decreased cTnI levels in diabetic
rats, but the differences did not reach statistical significance
4 Journal of Diabetes Research
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Figure 2: Plasma CK-MB (a) and cTnI (b) measurements after MIR. Plasma was, respectively, separated from blood samples immediately
collected after reperfusion. Data was expressed as mean ± SEM (𝑛 = 12 per group), I, T, S, and N, respectively, stand for ischemia-reperfusion
(I), Type 1 diabetes (T), sevoflurane (S), and N-Acetylcysteine (N); control: ischemia-reperfusion untreated group. ∗
𝑃
< 0.05; ∗∗
𝑃
< 0.01
compared with control group; ∧
𝑃
< 0.05 and ∧∧
𝑃
< 0.01 compared with T + I group.
(𝑃 > 0.05, T + I + S or T + I + N versus T + I). The synergy of
NAC and sevo-postC significantly reduced CK-MB and cTnI
levels in diabetic groups (𝑃 < 0.01, T + I + S + N versus T +
I).
3.4. The Protein Expression of p-STAT3, FoxO1, APN, and
CD36. As shown in Figure 3(a), p-STAT3 displayed lower
expression in all groups except I + S when compared with
control group (𝑃 < 0.01 versus control). Diabetes showed
significantly decreased p-STAT3 when compared with con-
trol group. Sevo-postCmade no difference in p-STAT3 either
in diabetic rat hearts or in normal ones. NAC remarkably
increased STAT3 phosphorylation (𝑃 < 0.01, T + I +N versus
T + I) and the combination of NAC and sevo-postC further
increased STAT3 phosphorylation in diabetic myocardium
(𝑃 < 0.01, T + I + N + S versus T + I or versus T
+ I + N). As described in Figure 3(b), all of the diabetic
groups showed increased Fox1 expression when compared
with control group (𝑃 < 0.05). NAC had a prominent effect
on the decrease of myocardial FoxO1 expression in diabetic
rats with or without sevo-postC (𝑃 < 0.01, T + I + N or
T + I + S + N versus T + I). In Figure 3(c), APN appeared
of obvious higher level in normal rats with sevo-postC than
in the control rats (𝑃 < 0.01). Sevo-postC significantly
increased myocardiac APN content in diabetic rats with or
withoutNAC (𝑃 < 0.01, T + I + S orT+ I + S+Nversus T+ I).
According to Figure 3(d), CD36 expressions were extremely
increased in diabetic groups compared to control group (𝑃 <
0.01). Sevo-postC markedly reduced CD36 level in normal
rat myocardium (𝑃 < 0.01, I + S versus control), while the
combination of NAC and sevo-postC significantly reduced
myocardial CD36 expression in diabetic rats (𝑃 < 0.01, T + I
+ S + N versus T + I).
4. Discussion
Numerous clinical treatments including thrombolytic ther-
apy, coronary artery bypass surgery, and cardiopulmonary
resuscitation can cause myocardial IRI. As an ideal inhaled
anesthetic, sevoflurane has beenwidely studied and proved to
have a protective effect on myocardium by means of precon-
ditioning or postconditioning implemented on laboratory
animals [1, 29]. Resistance induced by sevo-postC against
myocardial IRI in diabetic hearts remains to be confirmed,
and its mechanism is still not well explored. In the present
study, we found that, in the late stage (8 weeks of diabetes)
of STZ-induced diabetes, rats displayed the inactivation of
STAT3, APN deficiency, and the increase of FoxO1 and CD36
expression. Interestingly, the cardioprotective effect of sevo-
postC was lost in diabetic rats, which was restored by the
combination of NAC treatment. The possible mechanism
may be related to the increased expression of p-STAT3, APN
restoration, and the decreased expression of Fox1 and CD36
in diabetic rats.
Excessive oxidative stress, which can be accentuated by
hyperglycemia in diabetes, has been declared to aggravate
myocardial injury after IR [30]. Since NAC can reduce
myocardial dysfunction in diabetic heart [31], two groups of
the diabetic rats in the current study were treated with NAC
during the later stage (5 to 8 weeks) of the disease before
Journal of Diabetes Research 5
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Figure 3: Expression of myocardial p-STAT3 (a), FoxO1 (b), adiponectin (c), CD36 (d), and pictorial diagram of western blots (e) after
myocardial IR. Heart tissues were stored at −80∘C right after reperfusion. Data was expressed as mean ± SEM (𝑛 = 6 per group). I, T, S,
and N, respectively, stand for ischemia-reperfusion (I), Type 1 diabetes (T), sevoflurane (S), and N-Acetylcysteine (N); control: ischemia-
reperfusion untreated group. ∗
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being subjected to IR with or without sevo-postC. In this
study, we have observed that sevo-postC can decrease the
myocardial IRI in the normal rats reflexed as the decrease
of infarct size and cTnI release. In the severe or late stage
of diabetic rats, synergy between NAC and sevo-postC was
found to protect the myocardium against IRI reflexed as the
decrease of infarct size and CK-MB and cTnI secretion, while
NAC or sevo-IPostC alone did not help resist myocardial
IRI among diabetic groups. Interestingly, inconsistent with
infarct size and cTnI results, plasmaCK-MB levels showed no
significant difference between control and I + S groups. CK-
MB had been regarded as a diagnostic criterion ofmyocardial
infarction after acute myocardial infarction (AMI) [32, 33].
However, CK-MB release of patients who suffered AMI did
not reach a peak instantly but about 10 hours after ischemia,
and this peak value could be used to predict the myocardial
infarction which maximized 5∼7 days after reperfusion [32].
A similar conclusion was that, in diabetic rats, plasma CK-
MB and expansion of myocardial infarct size did not achieve
their highest levels simultaneously [34]. These investigations
suggested that myocardial infarct size could not always be
estimated precisely by CK-MB since CK-MB release can be
influenced by traumas such as tracheotomy, venipuncture,
and thoracotomy [35]. Since cTnI values and the infarct
size were defined as the golden standards evaluating the
severity of ischemic injury, our results indeed confirmed the
synergistically cardioprotection of NAC and sevo-postC in
diabetic rats.
Many studies have demonstrated that sevoflurane can
cause the cerebrovascular carbon dioxide reactivity and
delayed recovery of vecuronium neuromuscular block in
patients with diabetes [36, 37]. However, there are few reports
regarding cardioprotection induced by sevoflurane under the
condition of diabetes. Currently, the molecular mechanism
about resistance effects of sevo-postC against IRI is mainly
focused on PI3K-Akt, ERK1/2, andGSK-3𝛽, while Jak-STAT3
signaling pathway, which plays essential roles in myocardial
protection of postconditioning cardioprotection, is not well
investigated. As a downstream target of PI3K/Akt, FoxO1 can
presumably increase the sensibility of IRI in diabetic heart. In
this study, sevo-postC made no influence on p-STAT3, while
myocardial FoxO1 expression was enhanced in normal rats
after myocardial IR. In diabetes, the activation of myocardial
STAT3 was markedly decreased, whereas the expression of
FoxO1 was upregulated. The combination of NAC and sevo-
postC significantly increased STAT3 phosphorylation and
reduced FoxO1 levels in diabetic rat hearts, revealing a
protective effect against myocardial IRI. Studies have shown
that increased FoxO1 plays important roles in antioxida-
tion mediated by Sirt1 [38] and reduced myocardial IRI in
mice without diabetes [39]. The cardioprotection induced
by sphingosine-1-phosphate vanished that was accompanied
with the sustaining activation of FoxO1 in STAT-3 deficient
mice [13]. In the present study, cardiac FoxO1 was sup-
pressed accompanied with intensive STAT3 phosphorylation
in diabetic rats when administrated with NAC and sevo-
IPostC, which suggested that the possible mechanism may
be associated with STAT3mediated FoxO1 signaling pathway.
However, the effects of FoxO1 and/or STAT3/FoxO1 signaling
on myocardial IRI under normal or diabetic state require
more research to confirm.
APN is a protein that sensitizes insulin signaling and
improves metabolism, protecting against cardiac IRI [40, 41].
However, increasingAPN is also related to exacerbating heart
failure both in nondiabetic and in diabetic patients [42].
FoxO1, whose activation can be negatively regulated by APN
[23], is an importantmediator of diabetic cardiac dysfunction
[10]. FoxOs also increase mitochondrial CD36, which is the
predominant cardiac FA transporter and enhances FA uptake
[25]. In our study, we found that cardiac FoxO1 and CD36
are overexpressed with reduction of APN in diabetic rats.
The high expressions of FoxO1 and CD36 in diabetic groups
displayed an aggravating cardiac injury and suggested the
correlation between FoxO1, CD36, and lipid metabolism dis-
order in diabetes. The combination of NAC and sevo-postC
significantly decreased cardiac FoxO1 and CD36 expression
and restored APN expression, which contributed to the
attenuation of myocardial IRI. These findings indicated that
APN, FoxO1, and CD36 may functionally interact in NAC
and sevo-postC mediated cardioprotection in diabetes, but
their potential interplay in affecting diabetic myocardial
metabolism and sensitivity to IRI and IPostC needs further
study.
5. Conclusions
In summary, this study demonstrated that, in the late stage
of STZ-induced diabetes, rats displayed the inactivation of
STAT3, APN deficiency, and the increase of FoxO1 and
CD36 expression. Cardioprotection induced by sevo-postC
was abolished in diabetic rats. NAC and sevo-postC confer
synergy in reducing myocardial IRI in diabetes and the
possible mechanism may be associated with the increased
expression of p-STAT3, APN restoration, and the decreased
expression of Fox1 and CD36 in diabetic rats. The proposed
studies will help facilitate the development of novel and better
therapies for the management of ischemic heart disease in
diabetics in whom this disease is very common. It should be
noted that the occurrence of ischemia-reperfusion injury is
a complex pathological process that involves inflammation
and oxidative stress, and the potential attenuation of postis-
chemic inflammation and/or enhancement of endogenous
antioxidant enzymes might be attributable to the synergy
cardioprotection of join NAC and sevo-postC treatment that
deserves further studies.
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